SILBER ALLAN C 4
4 · POINT Biopharma Global Inc. · Filed Nov 21, 2022
Insider Transaction Report
Form 4
SILBER ALLAN C
Director
Transactions
- Purchase
Common Stock
2022-11-17$6.00/sh+27,603$165,618→ 4,246,208 total - Purchase
Common Stock
2022-11-18$6.50/sh+22,397$145,581→ 4,268,605 total
Holdings
- 538,087(indirect: By Trust)
Common Stock
- 313,884(indirect: By Spouse)
Common Stock
- 4,035,655(indirect: Silber Holdings, Inc.)
Common Stock
- 71,744(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.60, inclusive. The Reporting Person undertakes to provide to POINT Biopharma Global Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]Held in a trust for which the Reporting Person is the trustee.
- [F3]Silber Holdings, Inc. is a corporation controlled by the Reporting Person.
- [F4]Anglian Holdings, LLC is a limited liability company solely owned by the Reporting Person.